drugset / Trial / NCT07065617

A Study to Test How BI 1819479 is Taken up and Processed by the Body

NCT07065617

Phase 1 Terminated 7 enrolled Boehringer Ingelheim
Non-randomizedSequentialOpen-labelTreatment

Summary

This trial is intended to investigate the mass balance, metabolism, and basic pharmacokinetics of BI 1819479 (C-14) (Part A) and to investigate the absolute bioavailability of BI 1819479 (Part B) in healthy male volunteers.

Timeline

Start
2025-08-04
Primary completion
2025-10-04
Completion
2025-11-04

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1819479 Unknown

Indications

No indication recorded.